Jumonji Domain-Containing Proteins in Cancer Progression
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 17740
Special Issue Editors
Interests: Jumonji C domain-containing (JMJD) proteins; histones; epigenome; gene expression
Special Issue Information
Dear Colleagues,
Cancer cell growth is largely driven by the silencing of tumor-suppressor genes and/or the expression of oncogenes. Considerable amount of research has been undertaken to determine how these class of genes are regulated. Histone lysine methylation was first discovered in the 1960’s which gave rise to the study of enzymes named histone methyltransferases which have the ability to methylate specific lysine residues on histones to control gene transcription. It was long believed that lysine methylation was irreversible, until 2004 when the first histone demethylase was discovered. Since that time, Jumonji C Domain-Containing (JMJD) proteins were discovered which function to remove methyl groups from lysine and arginine residues on histones H3 and H4 to regulate gene expression. Similar to histone methyltransferases, histone demethylases have been implicated in cancer development and progression. Therefore, it is important to further determine whether JMJD proteins are potential therapeutic targets.
In this Special Issue on “Junomji Domain-Containing Proteins in Cancer Progression”, many aspects of the JMJD family proteins will be highlighted. We would like to invite scientists to submit manuscripts focusing on the JMJD proteins in cancer progression. Contributions to this Special Issue will cover in the format of reviews, original research articles, communications, and concept papers.
Prof. Dr. Sangphil Oh
Dr. William Berry
Guest Editors
Keywords
- Histones
- Epigenome
- Epigenetics
- Cancer
- Gene expression
- Jumonji Domain-Containing Proteins Demethylation
- Hydroxylation
- JMJD
- KDM